Physician profile
Michael Caplan
NPI 1225034549
$9,317.67
in general payments reported to CMS, 2019-2025
20 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $87.61 · 2021: $175 · 2022: $2,503 · 2023: $4,816 · 2024: $661 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,150 · Food and Beverage: $2,195 · Travel and Lodging: $706 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,150.00 |
| Food and Beverage | $2,195.31 |
| Travel and Lodging | $705.50 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,003.04 | 2019-2025 | Argos, Unity, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $388.13 | 2019-2024 | Tecnis Iol |
| Abbvie INC. | $371.54 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Glaukos Corporation | $318.09 | 2023-2024 | Idose |
| Carl Zeiss Meditec USA, INC. | $316.66 | 2021-2023 | Iolmaster 700 |
| Carl Zeiss Meditec, INC. | $206.55 | 2019-2020 | |
| Rxsight INC | $185.31 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $183.19 | 2023-2025 | Ic-8 Apthera Iol, Vyzulta |
| Sun Pharmaceutical Industries INC. | $62.57 | 2019-2025 | |
| Oyster Point Pharma, INC. | $45.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $43.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $41.69 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $31.41 | 2025 | Xdemvy |
| Dompe US, INC. | $30.95 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.47 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $21.42 | 2020 | |
| Allergan, INC. | $19.16 | 2021 | |
| Eyepoint US, INC. | $14.36 | 2019 | |
| Shire North American Group INC | $12.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.